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Abstract 
Tobacco smoke (TS) is the leading cause of preventable deaths worldwide. In addition to a host of well characterized 
diseases including chronic obstructive pulmonary disease, oral and peripheral cancers and cardiovascular complica-
tions, epidemiological evidence suggests that chronic smokers are at equal risk to develop neurological and neu-
rovascular complications such as multiple sclerosis, Alzheimer’s disease, stroke, vascular dementia and small vessel 
ischemic disease (SVID). Unfortunately, few direct neurotoxicology studies of tobacco smoking and its pathogenic 
pathways have been produced so far. A major link between TS and CNS disorders is the blood–brain barrier (BBB). In 
this review article, we summarize the current understanding of the toxicological impact of TS on BBB physiology and 
function and major compensatory mechanisms such as nrf2- ARE signaling and anti-inflammatory pathways activated 
by TS. In the same context, we discuss the controversial role of antioxidant supplementation as a prophylactic and/or 
therapeutic approach in delaying or decreasing the disease complications in smokers. Further, we cover a number of 
toxicological studies associated with “reduced exposure” cigarette products including electronic cigarettes. Finally, we 
provide insights on possible avenues for future research including mechanistic studies using direct inhalation rodent 
models.
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Background
Tobacco smoke (TS) is the leading cause of preventable 
death, accounting for more than 6 million premature 
annual deaths worldwide and over 480,000/year in the 
United States alone [1, 2]. Smoking and other tobacco 
use almost always begins at a young age and a large per-
centage continue to smoke as adults, becoming lifelong 
smokers. Currently about 5.6 million youths between 
0 and 17  years of age are estimated to die prematurely 
from smoking related illnesses. Both active and passive 
(second hand) smoking contributes to these high mortal-
ity rates with millions of smokers affected by a number 
of severe, smoking-related morbidities. In the US alone, 
these account for over $289 billion extra economic bur-
den including ≈$133 billion for direct medical care and 
≈$156 billion in productivity loss just for the years 2009–
2012 [1].
Lung cancer (29  %) [3] and ischemic heart disease 
such as atherosclerotic diseases of the myocardium and 
blood vessels (28 %) [4] are the two major fatal morbidi-
ties directly associated with smoking. Chronic obstruc-
tive pulmonary disease (COPD) (21 %) and other forms 
of cancer (8  %) closely follow. Less common morbidi-
ties that have been recently linked to smoking include 
declined immune functions, rheumatoid arthritis, dia-
betes mellitus, eye diseases (such age related macu-
lar degeneration) and inflammatory bowel disease [5]. 
Focusing on cerebrovascular disorders, epidemiological 
studies have associated smoking with the pathogenesis 
and/or progression of a number of major neurologi-
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cerebral infarction (SCI) [6], stroke [7] and small vessel 
ischemic disease (SVID; due to the pro-coagulant and 
atherogenic effects of smoking) [8, 9] and cerebral aneu-
rysms [10]. There is also a strong correlation between 
smoking and an increased risk for neurodegenerative dis-
orders such as multiple sclerosis [11, 12], Alzheimer’s dis-
ease, and neurodevelopmental damage during pregnancy 
[13]. Although some of the neuropathological effects of 
TS seem to be dependent upon nicotine-activated spe-
cific pathways [14], the precise cerebrovascular harm-
ful mechanisms triggered by TS remain largely unclear. 
However, recent studies clearly suggest that TS can trig-
ger a loss of blood–brain barrier (BBB) function and 
integrity which is certainly a critical prodromal factor for 
the pathogenesis of these neurological diseases.
Conceptual focus
In this review article, we will cover the current knowl-
edge and experimental data concerning the direct effects 
of tobacco smoking at the brain microvasculature with a 
special focus on the TS impact on BBB physiology and 
function. We will also illustrate the determining toxico-
logical factors of TS products including conventional and 
reduced exposure products such as electronic cigarettes. 
Using epidemiological evidence along with the limited 
body of direct toxicology studies, we then discuss the 
relationship of TS-induced toxicity with the increased 
risk and early onset of neurological/neurovascular com-
plications in the smoking population. Next, we review 
current literature that highlights the role of anti-oxidant 
based defense mechanisms such Nrf2-ARE signaling as 
well as anti-inflammatory pathways in coping with TS-
induced toxicity. In the same context, we will discuss 
the controversial role of antioxidant supplementation as 
a prophylactic and/or therapeutic approach to prevent 
the onset of disease complications or decrease their pro-
gression in smokers. Finally, we will provide insights on 
possible new avenues for future research including mech-
anistic studies involving direct inhalation rodent models.
The blood–brain barrier
The BBB is mainly composed of microvascular endothe-
lial cells (ECs) lining the luminal walls of the brain 
microvessels along with juxtaposed astrocytic end-feet 
processes and pericytes that support ECs differentia-
tion and maintenance of BBB properties [15, 16]. BBB 
endothelium is functionally distinct from ECs in other 
vascular beds because they are characterized by little 
pinocytotic activity, absence of fenestrations (i.e., open-
ings), and distinct distribution patterns of transmem-
brane transporters. These transporters strictly regulate 
the passage of nutrients and other essential elements 
while providing protection (e.g. efflux transporters) 
from possible harmful substances (both endogenous and 
xenobiotics). The strict tightness of the BBB ECs largely 
depend upon the presence of inter-endothelial tight junc-
tions (such as zonulae occludentes-ZO-1, occludin, clau-
dins, and junctional adhesion molecules-JAM) that form 
a physical barrier between adjacent endothelial cells thus, 
preventing the passage of hydrophilic substances through 
paracellular routes [17–19]. Another venue of entry 
across the BBB is controlled by asymmetrically distrib-
uted, carrier-mediated transport systems [20–22]. These 
allow the passage of water-soluble but biologically impor-
tant substances (e.g., d-glucose, amino acids, mono-
carboxylic acids, etc. [16, 17, 22]) from the peripheral 
circulation into brain parenchyma. The space between 
the endothelial cells also features junctional complexes 
of adherens junction (AJ) proteins such as VE-cadherin. 
Clearly, loss of AJ leads to increased permeability [23] but 
these proteins primarily assist the TJ which are primary 
determinants of BBB tightness. The dominant functions 
of these proteins include cellular adhesion, contact inhi-
bition and polarization of endothelial cells [24].
Apart from TJ and AJ proteins, specific efflux systems 
at the BBB (e.g., P-glycoprotein—P-gp [20], multidrug 
resistance associate protein 4—MRP4 [22] and breast 
cancer resistance protein-bcrp [25, 26]) limit the pas-
sage of potentially harmful amphipathic and hydrophobic 
substances by preventing their entry into the brain [20, 
27]. These transporters work in concert with several drug 
metabolizing enzymes (including monoamine oxidases 
and cytochrome P450s) via activation of the pregnane 
X receptor (PXR) also known as the steroid and xenobi-
otic sensing nuclear receptor) [28, 29] to efflux the pas-
sage of harmful substances into the brain [17]. Although 
the expression and functional activity of these metabolic 
enzymes has not been quantified relative to other organs, 
their presence at the BBB endothelium has been postu-
lated based on gene expression studies. For example, 
cytochrome P450 enzymes (e.g., P450 3A4) expressed at 
the BBB endothelial level under pathological conditions 
(e.g., drug-resistant epilepsy) [28, 29] were shown to 
actively metabolize carbamazepine into inactive deriva-
tives in BBB endothelial cells isolated from brain tissue 
resections of drug resistant epileptic patients. In addition 
to xenobiotics, these P450 enzymes metabolize endog-
enous lipids and steroidal hormones [30].
Impact of cigarette smoke on BBB and CNS
Cigarette smoking is considered a major risk factor for 
several neurological disorders and neurovascular com-
plications including stroke, SVID and vascular dementia. 
Preclinical and clinical findings published so far attrib-
ute oxidative and inflammatory damage caused by a 
large and still poorly identified number of highly reactive 
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oxidative species (ROS) contained in TS as the primary 
determinants of cigarette smoke-induced vascular toxi-
cology. In addition, neurological complications such 
as Alzheimer’s disease, multiple sclerosis, stroke, small 
vessel ischemic disease and vascular dementia [31–38] 
also report the involvement of ROS and inflammation 
as central mechanisms initiating and promoting disease 
progression. Thus, it is a viable possibility that chronic 
smoking exacerbates the overall damage due to oxidative 
and inflammatory stimuli and predisposes the end con-
sumer to these neuropathologies.
The BBB is rapidly exposed to this host of harmful 
toxicants and ROS present in TS which become a criti-
cal factor in TS-promoted CNS disorders. The BBB plays 
the crucial role of a dynamic interface which normally 
controls the passage of substances (both endogenous 
and xenobiotics) between the blood and the brain thus 
maintaining the brain homeostasis. When a cigarette puff 
is inhaled, a large number of soluble and gaseous com-
ponents within the smoke rapidly pass through the lung 
alveoli into the arterial circulation (skipping first pass 
metabolism) and quickly reach the brain microvascula-
ture. The brain parenchyma is effectively shielded from 
TS toxicants circulating in the blood by the BBB. How-
ever, chronic exposure to these substances may impact 
BBB viability and function overtime (e.g., lifelong chronic 
smokers). A functionally compromised BBB can then 
enable the onset and/or progression of neuroinflamma-
tory and neurovascular disorders [39, 40] which in turn 
can kick off a vicious cycle of continued BBB impairment.
Despite the strong evidence of an association between 
smoking and vascular impairment, the impact of ciga-
rette smoking on the BBB has only been marginally 
addressed. This is quite evident from the relative small 
number of basic and translational studies currently avail-
able in the literature. For example, the incidence of small 
vessel ischemic disease (SVID; a pathological condition 
characterized by loss of BBB integrity and leaky brain 
microvessels) in chronic smokers was shown to be signif-
icantly higher than non-smokers [41]. As a consequence 
of this disorder, patients typically manifest concerns 
such as gait problems, urinary continence and cognitive 
decline. The evidence of a leaky barrier in these patients 
was determined by measurements of S100β (a serum 
marker of blood–brain barrier integrity [41–44]) plasma 
extravasation and confirmed by Magnetic Resonance 
Imaging (MRI) scans showing widespread white and grey 
matter signals consistent with impaired BBB integrity 
[41].
In vitro toxicological testing of cigarette smoke using 
total TS particulate matter or soluble cigarette smoke 
extracts (CSE) is primarily focused on the lung and the 
cardiovascular system. However, the gaseous and soluble 
fractions quickly cross the lung alveoli, move into the 
arterial circulation and rapidly reach the cerebrovas-
cular network (and the BBB) right away. Current BBB 
toxicological studies are limited to assessing the harmful 
impact of whole soluble TS extracts or nicotine; the main 
tobacco neurostimulant component.
Previous work by our group using whole soluble TS 
extracts from research tobacco products (such as 3R4F; 
equivalent to conventional full flavor cigarettes) revealed 
a host of strong pro-inflammatory responses triggered 
by cigarette smoke at the BBB endothelial level [45]. The 
effect was significant both at the transcription and trans-
lational levels and included the up regulation of phase 1 
and 2 detoxification mechanisms, activation of the anti-
oxidant response pathways [46], up regulation of pro-
inflammatory cytokines, vascular adhesion molecules 
and increased leukocyte-endothelial interactions [41]. 
This strong inflammatory response is crucially relevant 
to define the impact of TS at the cerebrovascular level 
since vascular adhesion molecules facilitate the adhesion 
of monocyte to ECs and extravasation across the BBB 
[47]. Moreover, pro-inflammatory cytokines play a major 
role in the pathogenesis and modulation of inflammation 
[48] and have been shown to regulate the trafficking of 
immune cells across the BBB into the brain by acting as 
modulator of cytoskeleton TJ proteins and actin filaments 
[49]. In fact, a direct assessment of the BBB endothelium 
revealed a significant down regulation of major TJ pro-
teins such as ZO-1 and occludin paralleled by release of 
vascular endothelial growth factor-VEGF (a vasogenic 
factor that has been reported to play a major role in loss 
of BBB integrity [50]) and concomitant increase of para-
cellular permeability [46] (see also Fig. 1).
Apart from the whole soluble TS toxicants which 
seem to correlate well with oxidative stress generated by 
TS, nicotine exposure has shown to down regulate BBB 
endothelial tight junction protein expression such as 
ZO-1, occludin, cadherin, and adherens junctional pro-
teins [51–53]. In a separate study by Abbruscato et  al. 
nicotine exacerbated ischemic reperfusion (IR) injury 
and edema formation in experimental models of stroke 
[54]. Interestingly, the investigators observed a decrease 
in Na+/K+/2Cl− co-transporter activity following IR 
with prior nicotine and/or tobacco smoke exposure [52, 
55]. Furthermore; nicotine has been shown to promote 
angiogenesis in vitro in HUVECs and HCAECs mimick-
ing the effects of VEGF thus increasing capillary density 
and stimulating the growth of collateral blood vessels in 
mouse models of hind limb ischemia [56].
A noteworthy finding is the impact nicotine has on the 
drug disposition of saquinavir- an anti-retroviral drug 
used in Human Immunodeficiency Virus (HIV) therapy. 
The study reported that chronic exposure to nicotine 
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(delivered via subcutaneously osmotic pumps) impaired 
the activity of efflux transporters such as P-gp along with 
the loss of TJ protein ZO-1 and Notch-4 expression [57, 
58]. However, chronic nicotine exposure did not impede 
the passage of polar paracellular markers in sucrose per-
fusion studies. The same group also reported alterations 
in passive permeability or diffusion of compounds with 
low extraction values [59]. Although detailed in  vivo 
studies, based on chronic exposure of total whole solu-
ble TS toxicants and their impact on the BBB function 
and efflux transporters are warranted; so far the reported 
studies clearly indicate the overall potential of TS toxi-
cants to impact BBB function.
Fig. 1 Schematic representation of the brain microvasculature features and corresponding Impact of TS: a Schematic illustration of a cross sec-
tional view of a brain capillary. Note the endothelial cells are surrounded by supporting astrocytic end feet processes and pericytes along with the 
ensheathing basal lamina. b Paracellular passage of substances across the BBB endothelial layer is restricted by junctional protein complexes con-
sisting of TJ proteins (such as occludin, claudins, JAMs); along with adherens junction protein VE-cadherin and catenins. Note that the cytoplasmic 
accessory protein ZO-1 intercalates these intercellular proteins with the cytoskeleton. c TS-produced ROS promotes oxidative stress responses at 
the BBB endothelium. These include the activation of several transcription factors including Nf-κB and the antioxidant response system via nrf2-ARE 
pathway. This latter in turn activates anti-oxidant and detoxification genes. The downstream effect of TS exposure leads to the down regulation of TJ 
proteins; increase in vascular permeability and activation of pro-inflammatory responses leading to BBB dysfunction
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Regarding the pro-inflammatory activity of TS, ele-
vated levels of leukocytes are commonly observed in 
smokers [60]. In particular, neutrophils, which secrete 
free radicals, elastase and collagenase [61], are thought to 
contribute directly to EC injury. Platelet activation is also 
frequently observed [62], as confirmed by in  vitro and 
in vivo studies [63]. In conformity to a previous report by 
Nordskog, release and activity of matrix metalloprotein-
ase-2 and -9 [64] was also significantly increased. MMP-2 
and 9 primarily target the BBB by degrading components 
of the basal lamina and facilitating immune trafficking 
into the brain [65]. TS directly promoted the differentia-
tion of monocytes into macrophages independently from 
the presence of activated endothelial cells. Metallopro-
teinases such as MMP-9 are known to directly affect BBB 
integrity and have also been reported in immune cell traf-
ficking [66, 67]. The importance of these inflammatory 
events has been described in both in  vivo and in  vitro 
settings with the use of human aortic endothelial cells 
[68, 69]. Together with local infiltration and activation of 
circulating immune cells, these processes may contribute 
to the pathogenesis of vascular inflammatory disorders 
which have been linked to the onset and/or progression 
of several neuroinflammatory and neurovascular diseases 
[70, 71]. Previous studies from our group have also shown 
that tobacco smoke exposure impacts BBB endothelial 
inflammatory response at the gene transcriptional level 
[41, 46]. In fact, transcription of inflammatory modula-
tors such as NF-kappaB, RelB and STAT3 (which is also 
an angiogenesis modulator [72, 73] and a molecular 
linker for extracellular signals to transcriptional control 
of proliferation and immune evasion) were significantly 
upregulated by TS. Furthermore, SAA1 (a potent chem-
oattractant factor also responsible for the transcription of 
amyloid A [74]) and APOE (directly related to atheroscle-
rotic diseases and ischemic damage [75]) gene expression 
were also upregulated. Specifically APOE is responsible 
for the production of apolipoprotein E, which is essential 
for the normal catabolism of triglyceride-rich lipoprotein 
constituents. This polymorphic gene has been studied for 
its role in several biological processes related to immu-
noregulation and is associated with elevated cholesterol 
and risk of atherosclerosis and ischemic stroke.
Further, TS contains high concentrations of nitric 
oxide (NO) [76], which also can affect BBB integrity. NO 
plays critical role in controlling vascular tone, leukocyte-
endothelial adhesion and platelet aggregation. NO has 
been shown to modulate BBB function [77, 78] and is 
directly involved in a number of pathological processes 
inherent to inflammation. NO has a vasodilatory effect 
during the early stage of ischemic injury which appears 
to be protective for the brain [79]. This is early stage 
endothelial response promoted by eNOS activity is soon 
followed by activation of inducible NO synthase (iNOS) 
in inflammatory cells infiltrating the brain as well as the 
brain microvasculature leading to a massive spike of NO 
production (which peaks at 12–48  h after ischemia). 
Through a process of redox cycling NO is diverted 
toward the formation of peroxynitrite followed by pro-
duction of superoxide anion radicals O2− [80] which 
propagates inflammation to neighboring districts propa-
gating the damage. This ultimately results in the initiation 
and progression of vasculo-pathogenic diseases such as 
atherosclerosis, thrombosis.
Currently, vascular pathogenic processes activated in 
response to chronic tobacco smoking are far from being 
fully understood. Although, inflammation as well as oxi-
dative damage have been shown as major determinants of 
TS toxicity in studies published so far, additional studies 
both in vitro and in vivo will be necessary to break down 
the molecular targets and mechanisms involved. This is 
of critical importance in lieu of recent mechanistic stud-
ies outlining the parallel between cerebrovascular toxicity 
of tobacco smoke, its oxidative potential and the concur-
rent stimulation of a major antioxidant response system; 
the Nrf2-ARE pathway [46].
Nrf2‑ARE Pathway in cigarettes smoke‑induced 
oxidative stress
Nuclear factor (erythroid derived 2) like 2 known as 
NFEL2 or Nrf2 is a cap’n’collar (CNC) basic-region leu-
cine zipper (bZIP) transcription factor which plays a 
major role in countering oxidative stress [81–83]. Under 
basal conditions it is usually maintained at a low level in 
cytoplasm and bound to keap-1 which directs it to pro-
teasomal degradation. Gene polymorphisms in the pro-
moter region, post transcriptional modifications and 
protein–protein interactions have also been reported to 
modulate Nrf2 basal activity [84]. Of interest in the cur-
rent context, however, is the inducible response of Nrf2 
by TS-induced oxidative stress via ROS generation.
Under an oxidative stress insult, keap1 is ubiquitinated 
and Nrf2 becomes free to translocate from its cytoplasmic 
subcellular location into the nucleus. Upon binding to the 
antioxidant response element (ARE), it activates the tran-
scription of several downstream genes mainly involved 
in detoxification and antioxidant processes [83, 85]. The 
major downstream effectors of the ARE pathway can be 
classified into the following main categories: (1) detoxi-
fication system including Phase I (oxidation/reduction), 
Phase II (conjugation enzymes) and Phase III (drug efflux 
transporters) [83, 85]. The Phase I genes are involved in 
oxidation/reduction/hydrolysis biochemical functions 
including enzymes belonging to the aldo–keto reductase 
family, aldehyde and alcohol dehydrogenases, cytochrome 
P450, NAD(P)H: Quinone reductase I (NQO1) and 
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carbonyl reductase (CR) to name a few. Substances then 
enter Phase II where they are conjugated to bulky polar 
groups such glutathione, glucoronic acid, sulfate or gly-
cine and converted into more readily excretable forms. 
Apart from these biochemical reactions, potentially 
harmful compounds are also kept out of the cell through 
the activity of efflux transporters belonging to the ATP 
binding cassette (ABC) family; (2) antioxidant system 
(including glutathione—GSH and thioredoxin); (3) heme 
and iron metabolism; (4) Carbohydrate and lipid metabo-
lism; (5) cross talk between transcription factors.
Many studies report high transcriptional activity of 
these factors in several disease models of acute and 
chronic oxidative or inflammatory injuries in the brain as 
well as other peripheral organs. These include disorders 
related to oxidative and/or inflammation such as diabetes 
[86, 87], ischemia reperfusion injuries [88, 89], cardio-
myopathies and heart failure [90], liver fibrosis [91], and 
chronic kidney disease [92]. Activation of the Nrf2 path-
way and up regulation of several downstream effector 
proteins has also been reported specifically due to ciga-
rette smoking on resident macrophages, lung bronchial 
and alveolar epithelium and lung fibroblasts of chronic 
smokers [93]. Nrf2 activation has been shown to play a 
major coping role against the onset and progression of 
COPD and emphysema- major disorders associated with 
smoking [81, 94, 95].
Unfortunately, the vast majority of current literature 
concerning the mechanistic details of TS toxicity pri-
marily covers the pulmonary and cardiovascular systems 
leaving the cerebrovascular system poorly understud-
ied. This remains a critical issue to be addressed since 
the importance of the Nrf2-ARE pathways at the brain 
microvascular level have been clearly emphasized by a 
number of recent studies focused on cerebrovascular oxi-
dative stress injuries. These injuries include stroke (both 
global and focal ischemia) [96], subarachnoid brain hem-
orrhage [97], amyotrophic lateral sclerosis (ALS) [98], 
multiple sclerosis (MS) [99] and Alzheimer’s disease (AD) 
[100] and diabetes [101, 102]. Interestingly, the impact of 
Nrf2 signaling has been reiterated in several recent, pre-
clinical studies which have clearly shown that boosting 
antioxidant pathways through Nrf2 enhancers or antioxi-
dant supplements such as docosahexaenoic acid (DHA), 
resveratrol, bicyclol can be beneficial in neuropatholo-
gies such as cerebral stroke [103–105]. Nrf2 has shown 
to play a cytoprotective role against TS exposure in BBB 
endothelial cells. Our group has observed nuclear trans-
location of Nrf2 followed by increased transcription (and 
translation) of detoxification enzymes and anti-oxidants 
in response to TS exposure [46].
In contrast, a number of clinical and preclinical stud-
ies concerning the effects of chronic smoke have revealed 
that the organs exposed to TS manifested a defective and 
compromised Nrf2 signaling [106, 107]. One such study 
highlighted the inhibition of the Nrf2/ARE pathway due 
to cigarette smoking in peripheral mononuclear cells of 
young heavy smokers which promoted inflammation and 
exacerbated damage [108].
Unfortunately, to date, the pathobiology of cigarette 
smoking at the brain and brain microvascular level is 
still poorly understood. How these pathways are acti-
vated and if chronic TS exposure can impact Nrf2-based 
mechanisms operating at the BBB level is a question still 
open for investigation. It is therefore evident that there is 
urgent need to identify new avenues of intervention for 
reducing the risk of cerebrovascular disorders in smokers 
and, perhaps, accelerate the recovery of the antioxidant 
system during smoking cessation.
Antioxidant supplementation in smokers: 
where do we stand today?
Tobacco smoke generates superoxide and other reactive 
oxygen species which promote DNA strand breakage 
[109–112], release of nitric oxide (NO) and antioxidant 
depletion (e.g., ascorbic acid). Under normal conditions, 
ROS are cleared by the intracellular action of superox-
ide dismutase (SOD), catalase, glutathione (GSH) per-
oxidase [113] or extracellular antioxidant vitamins such 
as ascorbic acid (vitamin C), and α-tocopherol (vitamin 
E) [114–117]. However, environmental factors includ-
ing active and passive TS spawn sustained high levels 
of ROS beyond the ability of the human body to effec-
tively eliminate them. In fact, several studies have shown 
that chronic smokers suffer from antioxidant shortages 
caused by increased anti-oxidative mobilization evoked 
by TS [118–120]. Over time (e.g., chronic smokers) this 
imbalance is likely to promote oxidative damage both to 
cells and tissues. A recently published study by our group 
[45] has demonstrated that TS contains high concentra-
tions of NO and ROS leading to the initiation and pro-
gression of various vasculopathies (e.g., atherosclerosis, 
thrombosis) as well as BBB damage. Indeed, the current 
scientific opinion considers ROS-mediated pathways to 
contribute significantly to the pathogenesis of many neu-
rological diseases. This hypothesis is strongly supported 
by in  vivo and in  vitro experiments where antioxidant 
supplementation prevents oxidative damage and inflam-
mation induced by cigarette smoke. Even the Food and 
Nutrition Board of the National Academy of Sciences 
has established a higher recommended dietary allowance 
(RDA) of vitamin C for smokers (over 200 mg/day versus 
the recommended 90  mg/day for non-smokers). How-
ever, clinical studies have shown a number of contrast-
ing results with in vitro and/or in vivo studies regarding 
the therapeutic effect of antioxidants in a number of 
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neurovascular/neurodegenerative disorders [121–125]. 
This makes it challenging to argue for or against the 
prophylactic and/or therapeutic use of anti-oxidants 
in smokers. Recent observations suggest that ROS are 
key mediators of BBB breakdown [126] and antioxidant 
supplementation has proven to be beneficial in alleviat-
ing a loss of BBB integrity and a vascular inflammatory 
response in smoke-exposed in  vitro BBB cultures [127]. 
Although there is still no unequivocal evidence that an 
increased intake of antioxidant nutrients can effectively 
counteract TS toxicity, there is supporting data suggest-
ing that antioxidants may prove to be effective scavengers 
of exogenous (TS-like)-derived ROS [128]. For exam-
ple, vitamin C prevents histamine release and increases 
the detoxification of histamine [129], thus acting as an 
anti-inflammatory agent as well as a potent antioxidant. 
Vitamin E on the other hand has been shown to be cardi-
oprotective against tobacco smoke-induced peroxidative 
damage [130–132] and can be a beneficial adjuvant in 
the treatment of seizures, diabetes and in the reduction 
of post-ischemic damage [133–136]. Recently published 
in vitro studies by our lab have clearly shown that both 
vitamin C and E can effectively protect the BBB against 
TS-generated oxidative damage [127]. Nevertheless, at 
this point the use of antioxidants (including Nrf2 enhanc-
ers) needs to be considered with caution. To illustrate 
this, in most cases there is not a far reaching consensus in 
the clinical setting regarding dosing parameters, (includ-
ing frequency of administration). Recently published 
preclinical studies also indicate that cancerous cells pri-
oritize Nrf2 activation to promote their survival from 
antioxidant damage [137, 138]. Furthermore, high-mobil-
ity group protein B1 (HMGB1; a mediator of inflamma-
tion produced by necrotic tissue and activated immune 
cells) appears to be involved in the post-ischemic inflam-
matory response and has been correlated to poor func-
tional outcome [139–141]. Because the redox state of the 
intra- and extracellular environments control the activ-
ity of HMGB1-mediated pro-inflammatory signaling 
[142, 143], post-ischemic administration of antioxidants 
(therapeutic administration) may instead prolong and 
intensify the pro-inflammatory stimulation at the site of 
injury by neutralizing the ROS required to abate HMGB1 
activity. Considering these premises, it is clear that more 
detailed and well-designed/standardized studies will be 
necessary to solve this impasse.
Working around cigarette toxicity from an industry 
perspective
Reduced exposure cigarette products
Cigarette smoke consists of about 7000 different chemi-
cals and potential toxicants which may be included in 
either the gas and/or the particulate fractions of TS. Tar 
is defined as the dry solid residue deriving from the com-
bustion of tobacco which yields the particulate fraction of 
cigarette smoke. This is often termed as TPM which con-
tains nicotine as well as numerous carcinogens, chlorin-
ated dioxins, furans metals, poly aromatic hydrocarbons 
(PAH), nitrosamines, terpenoids, and paraffin waxes 
[144, 145]. The gas phase of cigarette smoke includes 
gases of combustion such as carbon dioxide (CO2), car-
bon monoxide (CO), nitrogen (N2), oxygen (O2), hydro-
gen cyanide (HCN), hydrogen sulfide (H2S), nitric acid, 
acetone, acrolein, acetaldehyde, methane, ammonia, 
methanol, along with hydrocarbons, gas phase nitrosa-
mines [(N-nitrosoanabasine (NAB), N-nitrosoanabatine 
(NAT), 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone 
(NNK), and nitrosonornicotine (NNN)] and carbonyl 
compounds [144]. In addition, exposure to these sub-
stances can increase intracellular levels of ROS through 
enhanced mitochondrial activity [146–149]. This ulti-
mately can lead to the formation of adducts at lipids, 
proteins and DNA level such as 4-hydroxy-nonenal 
(4-HNE) and lipid peroxidation products [150–152], pro-
tein carbonyls [153, 154] and DNA adducts [150, 155] 
respectively.
Due to the complex nature of identifying and deter-
mining these toxicants, which may vary according to 
the fabrication procedure of the various cigarette brands 
and lack of central control in their manufacture, the 
FDA initiated an independent center dedicated to the 
production and distribution of standardized research 
tobacco products (reference cigarettes) in 2009 reflect-
ing the main cigarette denominations currently available 
in the market (e.g., 3R4F—full flavor; 1R5F, light flavor). 
The tobacco industry has developed “reduced exposure” 
and “light” cigarettes containing lower levels of nicotine, 
nitrosamines or other chemicals deemed to be potentially 
toxic. However, the underlying claim that these products 
are safer than conventional cigarettes is not supported 
by experimental and/or clinical data. Recent smokeless 
tobacco products are marketed to current and “potential” 
smokers as a safer alternative to conventional products. 
At the same time, these “light” products also contain a 
certain amount of tobacco specific nitrosamines. There 
is a significant difference between these “light” cigarettes 
versus products that deliver tobacco-free nicotine, such 
as nicotine replacement therapies (NRT’s, e.g., nico-
tine gum, lozenge and inhaler) or electronic cigarettes 
(e-cigarettes).
Recent reports using whole soluble TS extracts from 
conventional and reduced exposure products (includ-
ing ultralow nicotine—ULN—cigarettes obtained from 
National Institute of Drug Abuse-NIDA) revealed that 
the total oxidative and nitrosative capacity as well as pro-
inflammatory activity of ULN (a cigarette containing 
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negligible nicotine but quantities of tar comparable to 
conventional full flavor products) and nicotine free- NF 
(non-tobacco based) cigarettes were comparable or even 
worse than conventional cigarettes [45] thus negatively 
affecting the brain microvascular endothelium [45, 46, 
156]. This creates quite a confusion as to what extent and 
in which form these reduced exposure products are to be 
considered safer than their conventional counterparts.
E‑cigarettes
Electronic (e-) -cigarettes are members of the recently 
marketed electronic nicotine delivery devices (ENDDs). 
E-cigarettes can be primarily described as electronic, 
smokeless, nicotine delivery systems simulating cigarette 
smoking independently of the combustion of tobacco. 
There are at least 400 different brands of e-cigarettes 
currently available in the market (see Table  1 for a list 
of brands) [157]. E-cigarettes contain a fluid-filled car-
tridge (including numerous ingredients such as vegetable 
glycerin (VG) responsible for the visible vapor, propylene 
glycol (PG) serving as a flavor diluent, nicotine, menthol 
and other flavoring agents), an atomizer (which vapor-
ize the e-liquid by heat) and a power source consisting 
of a rechargeable battery that charges the atomizer (see 
Fig.  2). Puffing on the e-cigarette vaporizes the fluid, 
allowing for the appearance of a “vape” which is deliv-
ered to the airways and from there across the lung alveoli 
into the circulatory system. To date, about three genera-
tions of e-cigarette designs have come up in the market 
with higher battery capacities, more heating power and 
sophisticated models although relying on the same basic 
components and principles highlighted above.
Nicotine, the main vape component, is present in the 
maximum range of 20  mg/ml [158]. The vapor forma-
tion after heating of the e-liquid is not consistent. It is 
dependent on the product design, and puffing parameters 
including puffing rate/duration/volume. Nevertheless, 
the absorption of nicotine is reported as considerably less 
Table 1 List of brand of e‑cigarettes currently available in market
E-cigarettes Design features Popular e-cigarette products
under the Brand
Vapor Fi Two-piece sophisticated designs
Selection of refillable tank-style e-cigarettes with good vapor 
production
Offers over 30000 flavors
Range of tank sizes and battery power
Variable voltage/airflow
Express starter and Pro starter kit for beginners
VaporFi Rocket—for more experienced users
1 Rocket Tank with 1 dual coil and fully adjustable airflow control
Vox II mod—stronger vape
50 watts of power vaporizer (adjustable)
V2 Cigs Two-piece design with disposable as well as refillable versions
Newer line of product designs available includes the V2 Pro
Makes their own e-liquid with 24 flavor options
Provides battery options with both manual as well as automatic 
version
EX line of e-cigarettes are the top miniatures, pen-style e-cigarettes
V2 Pro series
Cartridge recognition to optimize the temperature of the atomizer
Can vaporize three types of ingredients
V2 Disposables and Zig-ZagTm are disposable e-cigarettes
Green smoke Two-piece design disposable cartomizer system in a range of 
flavored cartridges
Designed for beginners
FlavorMaxTm cartridge holds the e-liquid and the unit
Available in different sized starter kits and packs
Halo cigs Halo Cigs offer a well-built product with mainly two designs (Halo 
G6 e-cig. and Triton Vape pen)
Makes their own e-liquid
Halo G6 rechargeable e-cigarette
Leak proof and refillable e-cig cartomizers
Different size tank options
Triton vape pen
e-cig with a leak-proof vape tank
Variable voltage long-lasting batteries
Apollo Advanced clearomizer (cartomizers with clear bodies) technology
Makes their own e liquid (25 flavors available); Refillable as well as 
disposable versions
Range of battery options from low to higher power output
Extreme kit (low battery power for new users)
Endevour kit (Intermediate battery power)
Vtube kit (maximum vape/battery power with variable voltage 
option; generally, for heavy smokers)
Apollo Disposable and E-cigar
Disposable products
Blu Cigs Two-piece sleek design in disposable or prefilled designs (with blu 
TankTm or flavor cartridges)
Signature blue LED tip: Lights up to let you know that your blu 
e-cig is working
Silicone tip: Intake maximizes each draw
Blu rechargeable e-cigarette (blu flavor cartridge with rechargeable 
battery that charges in the USB chargeable pack);
PLUS + rechargeable™ (6-hole tip, more powerful 
PLUS + rechargeable battery and blu™ tank)
Blu™ disposable electronic cigarettes
EverSmoke Looks and feel like a real cigarette
Two battery sizes and range of flavored cartridges with a Silicone 
Tip
VaporFlo™ technology for smooth draw
EverSmoke Electronic Cigarette (tobacco, menthol and other 
flavored rechargeable cartridges)
Available in different sized starter kits and packs
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than conventional “combustion-based” counterpart prod-
ucts. Other major components of the e-liquid are propyl-
ene and diethylene glycol. Release of these glycols in the 
vapor is estimated to be with-in safe limits based on some 
recent reports [159]. However, whether they undergo fur-
ther physicochemical modification (by the heat necessary 
to vaporize the e-liquid) into more harmful compounds 
has not been investigated. Further, there are no defined 
parameters and established guidelines concerning prepa-
ration of the e-liquids and their composition which adds 
serious safety concerns regarding e-cigarettes.
Increasing the market appeal is their wide range of 
flavoring agents that can be added to the e-liquid mix 
such as vanillin, cinnamon, various fruits, menthol, etc. 
to name a few. These flavoring agents which are proven 
safe for use in food or confectionary products (ingested) 
are assumed to be equally safe when vaporized in the 
form of e-liquids (inhaled). Limited but steady evidence 
clearly suggests that these flavoring chemicals are present 
beyond the National Institute for Occupational Safety 
and Health (NIOSH) safety range and can be a potential 
irritant when directly inhaled [159–162].
Toxicological data currently available 
about e‑cigarettes
First introduced into the consumer market in 2005, the 
global market for ENDDs has rapidly expanded. It has 
been predicted that within the next decade, sales of 
ENDDs will surpass that of traditional tobacco-based 
cigarettes. In 2011, it was estimated that 21 % of US adult 
cigarette smokers had tried an ENDD [163] which are 
also quite popular among adolescents and young adults 
[164]. The rapid rise of ENDD use has divided the pub-
lic health and tobacco control community [165, 166]. 
Although there is potential for public health harm reduc-
tion through decreased use of combustible tobacco prod-
ucts [167, 168], there are significant concerns about the 
limited scientific information with respect to the short 
and long-term effects on human health as well as their 
intrinsic potential to attract new and former smokers. 
A high percentage of former smokers are reported to 
choose e-cigarettes in an effort to quit smoking and/or 
to allow for smoking in situations where traditional ciga-
rettes are not allowed [169] due to the popular percep-
tion of their relative safety [170–173]. Thus, the addictive 
potential of e-cigarettes is also a major concern.
A critical barrier for the Food and Drug Administra-
tion’s (FDA’s) Center for Tobacco Products (CTP) regu-
lation of all types of cigarettes is the identification of 
constituents that are harmful to human health. Sadly 
enough, clinical and preclinical studies supporting the 
conceptual claims that e-cigarettes are significantly safer 
than conventional tobacco products are not backed by a 
body of research evidence. There are a handful of toxico-
logical studies on e-cigarettes that have mainly focused 
on limited cytotoxicity assessments without considering 
the detailed vapor composition inhaled by the end-user 
[161]. Moreover, these studies are limited and to date, 
have only been performed in vitro on a limited number of 
cell phenotypes such as pulmonary fibroblasts, bronchial 
epithelial cells, embryonic stem cells, and neural stem 
cells [174–176]. Although these reports suggest e-liquids 
to be safe, there are some observed differences in cyto-
toxicities attributed to the flavors used. Apart from cyto-
toxicity assays there are also some chemical assay reports 
suggesting that, in respect to the content of tobacco spe-
cific nitrosamines (TSNAs), carbonyls, volatile organic 
compounds (VOC) and heavy metals, e-cigarettes are 
relatively safer [177]. However, analyses of the e-liquid 
revealed the presence of residual aromatic hydrocar-
bons, formaldehyde, acetone, minor tobacco metabolites 
(e.g., anabasine, myosmine, β-nicotyrine), propylene gly-
col, diethylene glycol, and tobacco specific nitrosamines 
including carcinogens in a wide range of concentrations, 
thus suggesting a lack of standardization of the raw mate-
rials and/or manufacturing processes [159, 161]. Further, 
some constituents of e-cigarette vapor (e.g., flavoring 
agents) not present in conventional tobacco smoke have 
been shown to be cytotoxic in embryonic/adult cellular 
models [178] and/or represent a possible environmental 
hazard such as copper [179].
Thus, there are many brands of e-cigarettes currently 
available in market (as illustrated in Table  1). Due to 
lack of current regulatory systems each brand produces 
its own e-liquids which differ for composition, including 
Fig. 2 Schematic illustration of a typical e-cigarette: This device 
mainly consists of a cartridge containing nicotine dissolved in an 
e-liquid which also contains flavoring agents; an atomizer that vapor-
izes the e-liquid and a rechargeable battery (sometimes with a LED 
indicator) that provides power to the atomizer. The atomizer and 
the cartridge are sometimes collectively called the cartomizer. The 
battery output and the resistance of the heating coils determine the 
vaping capacity of the device
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flavoring agents, nicotine concentration, solvent con-
stituents such as propylene glycol and vegetable oils 
as well as different levels of heating power. These many 
variabilities in e-cigarette brands may directly impact the 
toxicity profile of the final products. These warrant for 
comparative toxicological studies which will be necessary 
to inform the FDA and generate common manufacturing 
guidelines. In this regard, the most recent safety studies 
have been limited to the analysis of heating byproduct 
derivatives and corresponding direct toxicological assess-
ments (both qualitative and organ specific) [179–181]. 
Direct vaping of the e-liquid and inhalation studies using 
preclinical animal models first requires standardization 
of methods and delivery of the vape to mimic common 
inhalation patterns of e-cigarettes in the end user. Only 
then can short and long term toxicological studies on 
e-cigarettes be reliably planned and executed. Moreo-
ver, these toxicology studies need to address not only the 
primary sites of inhalation (such as the oral cavity, lung 
mucosa and the cardiovasculature) but also should be 
extended to brain and the brain microvasculature. Such 
preclinical toxicological studies are essential to support 
the regulatory authorities and to set quality standards of 
this product with the concern of public health in mind.
Unknown health impacts and new regulatory 
challenges regarding e‑cigarette
The Family Smoking Prevention and Tobacco Control 
Act (FSPTCA) gave the FDA the authority to regulate 
the manufacture, marketing and distribution of tobacco 
products. This authority includes the review of new and 
modified tobacco products prior to their introduction to 
the market and to establish standards for tobacco prod-
ucts. A recently conducted worldwide survey found that 
both former smokers and current heavy smokers ini-
tiated e-cigarette use based on the perceived benefits 
of lack of toxicity and negligible effects of second hand 
smoking exposure for their families [182] versus the use 
of regular products. These surveys clearly indicate the 
end-consumer is making serious health decisions based 
on the commercial claims of these products. Consumers 
assume that e-cigarettes prolong abstinence and/or pro-
mote a more effective smoking cessation program than 
RTS. However, current clinical studies are inconclusive 
[183, 184] and, therefore, e-cigarettes provide uncertain 
benefit in quitting smoking. The CTP division of the FDA 
currently monitors and reviews cigarettes, roll-your-own 
tobacco and smokeless tobacco. However, due to the 
alarming concern over the use of e-cigarettes, it initi-
ated public forums to report adverse events and toxici-
ties associated with the use of new electronic devices. In 
addition, it has recently proposed a rule to extend the 
regulation of these newly “deemed” products (such as 
e-cigarettes) which are incorporated under CTP regula-
tory monitoring.
Conclusion and future perspectives
Although, epidemiological evidence and clinical studies 
have clearly shown that tobacco smoking is a major risk 
factor for the pathogenesis of several neuro-inflammatory 
and neurovascular disorders [6, 185, 186], detailed toxi-
cological and mechanistic studies focused on TS effects 
at the brain and brain microvasculature are quite scarce. 
The few basic studies addressing this crucial issue have 
shown that TS exposure is likely to impact BBB physiol-
ogy and functions by promoting oxidative stress damage 
and inflammation. Although indicative of the potential 
TS toxicity at the BBB, these studies have been limited at 
large to in vitro settings following acute or limited chronic 
exposure which may not fully recapitulate the complex 
dynamics of a physiological setting. Studies in  vivo have 
been limited to a handful of constituents (mainly nicotine) 
contained within the several thousands of compounds 
found in TS. Therefore, there is a clear lack of knowledge 
in regard to TS cerebrovascular toxicity that needs to be 
addressed. Direct chronic smoke inhalation studies in vivo 
along with assay of the additional physiological alterations 
(e.g., blood hemostasis, neuroinflammatory biomarkers, 
etc.) will be necessary to gather realistic data in a setting 
that more closely mimics the smoking patterns of the end 
user. Additional mechanistic insights will enable us to 
elucidate the antioxidant as well as inflammation based 
cytoprotective mechanisms at the BBB level and their 
overall capacity to sustained the oxidant load generated 
by TS as well as other oxidative stimuli. This will take us 
a practical and important step forward in understanding 
the health risk associated with tobacco smoking regard-
ing the onset of neurovascular and neuro-inflammatory 
diseases such as cerebrovascular stroke, diabetes, Alzhei-
mer’s disease, SVID, vascular dementia and multiple scle-
rosis. These data could be also used to identify a number 
of putative prognostic biomarkers to assess the smoker 
risks for the pathogenesis and/or progression of neuro-
logical disorders. Apart from these studies largely focused 
on the mechanistic component, therapeutic studies aimed 
at the betterment of health outcomes of the smoking 
population are equally crucial. In that direction, the use 
of Nrf2 enhancers has demonstrated impressive results to 
improve cerebrovascular pathologies such as stroke out-
comes [103, 187]. Nrf2 driven activation of ARE pathway 
may be compromised in a BBB that is chronically exposed 
to tobacco smoke (TS); which in an event of cerebro-
vascular ischemic insult may lead to exacerbated loss of 
BBB integrity/function and secondary brain injury. These 
enhancers (or activators) can potentially benefit the health 
of the smokers through improved anti-oxidant capacity 
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along with smoke cessation or reduction aids currently 
available in the market.
Concerning reduced exposures tobacco products, cur-
rently available toxicological studies examining the cer-
ebrovascular system and the CNS are very scarce. For 
products recently introduces in the consumer marker 
such as e-cigarettes, the lack of toxicological data is even 
more dramatic considering that the very limited number 
of studies published so far focus most exclusively on the 
respiratory system. In addition, standardized toxicologi-
cal testing paradigms to compare e-cigarettes versus tra-
ditional tobacco products have not been developed. The 
urgency of filling this gap is strongly dictated by a num-
ber of population-based studies suggesting that the use 
of e-cigarettes (especially among young individuals) will 
soon surpass that of conventional cigarettes. Enforce-
ment of Good Manufacturing Practices is also a “must” 
to ensure quality standards in the preparation of the 
tobacco products including e-liquids and safety of the 
main raw materials utilized.
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